What’s new in Sjögren syndrome: (1) clinical clues herald progression to a life-threatening variant and (2) a common therapy exacerbates comorbidities.
References1. Retamozo S, Flores-Chavez A, Kostov B, et al. Severe, Life-Threatening Phenotype of Primary SjÃ¶gren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry) [Abstract 1564]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 22, 2018.2. Baldini C, Ferro F, Luciano N, et al. Comorbidity Burden in Primary SjÃ¶gren’s Syndrome: A Long-Term Observation in Clinical Practice [Abstract 1565]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 22, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.
Two studies presented at the American College of Rheumatology (ACR 2018) annual meeting in Chicago, IL, address the outcomes and comorbidities associated with SjÃ¶gren syndrome. In the first study, Retamozo and colleagues in Spain found that 13% of patients with SjÃ¶gren syndrome develop systemic disease-leading to death in as many as 20%.1 In the second study, Baldini and fellow researchers in Italy discovered that glucocorticoid therapy exacerbates comorbidities in patients with primary SjÃ¶gren syndrome.2 Scroll through the slides for the details of the two studies and the take-home points for clinicians.
DMARD, disease-modifying antirheumatic drug; ESSDAI, European League Against Rheumatism SjÃ¶gren’s Syndrome Disease Activity Index.